Role of Human Leukocyte Antigen System As A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Oct 7

PMID 33023239

Citations 41

Authors

Francesco Sabbatino

Luigi Liguori

Giovanna Polcaro

Ilaria Salvato

Gaetano Caramori

Francesco A Salzano

Vincenzo Casolaro

Cristiana Stellato

Jessica Dal Col

Stefano Pepe

Affiliations

Soon will be listed here.

Abstract

Recent advances in cancer immunotherapy have clearly shown that checkpoint-based immunotherapy is effective in a small subgroup of cancer patients. However, no effective predictive biomarker has been identified so far. The major histocompatibility complex, better known in humans as human leukocyte antigen (HLA), is a very polymorphic gene complex consisting of more than 200 genes. It has a crucial role in activating an appropriate host immune response against pathogens and tumor cells by discriminating self and non-self peptides. Several lines of evidence have shown that down-regulation of expression of HLA class I antigen derived peptide complexes by cancer cells is a mechanism of tumor immune escape and is often associated to poor prognosis in cancer patients. In addition, it has also been shown that HLA class I and II antigen expression, as well as defects in the antigen processing machinery complex, may predict tumor responses in cancer immunotherapy. Nevertheless, the role of HLA in predicting tumor responses to checkpoint-based immunotherapy is still debated. In this review, firstly, we will describe the structure and function of the HLA system. Secondly, we will summarize the HLA defects and their clinical significance in cancer patients. Thirdly, we will review the potential role of the HLA as a predictive biomarker for checkpoint-based immunotherapy in cancer patients. Lastly, we will discuss the potential strategies that may restore HLA function to implement novel therapeutic strategies in cancer patients.

Citing Articles

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study.

Liguori L, Giorgio G, Polcaro G, Pagliara V, Malandrino D, Perri F Front Immunol. 2024; 15:1419544.

PMID: 39664396 PMC: 11631946. DOI: 10.3389/fimmu.2024.1419544.

Causal relationship, shared genes between rheumatoid arthritis and pulp and periapical disease: evidence from GWAS and transcriptome data.

Wu H, Wang L, Qiu C Front Immunol. 2024; 15:1440753.

PMID: 39346909 PMC: 11427265. DOI: 10.3389/fimmu.2024.1440753.

Effect of Isoscopoletin on Cytokine Expression in HaCaT Keratinocytes and RBL-2H3 Basophils: Preliminary Study.

Seo D, Park J, Kim S, Oh S, Han S, Kwon O Int J Mol Sci. 2024; 25(13).

PMID: 39000019 PMC: 11240891. DOI: 10.3390/ijms25136908.

MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease.

Slotta-Huspenina J, Schwamborn K, Steiger K, Simon R, Kirchhoff F, Buchler J Bladder Cancer. 2024; 8(3):269-276.

PMID: 38993685 PMC: 11181837. DOI: 10.3233/BLC-211604.

The relationship between innate/adaptive immunity and gastrointestinal cancer : a multi-omics Mendelian randomization study.

Lv C, Zhou L, Yang Y, Shi J, Dong F, Wei H BMC Gastroenterol. 2024; 24(1):197.

PMID: 38877387 PMC: 11177483. DOI: 10.1186/s12876-024-03284-x.

References

Sant A, Yewdell J . Antigen processing and recognition. Curr Opin Immunol. 2002; 15(1):66-8. DOI: 10.1016/s0952-7915(02)00020-1. View

Rechsteiner M, Hoffman L, Dubiel W . The multicatalytic and 26 S proteases. J Biol Chem. 1993; 268(9):6065-8. View

Robbins G, Truax A, Davis B, Zhang L, Brickey W, Ting J . Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. J Biol Chem. 2012; 287(29):24294-303. PMC: 3397855. DOI: 10.1074/jbc.M112.364604. View

Chang C, Flavell R . Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med. 1995; 181(2):765-7. PMC: 2191893. DOI: 10.1084/jem.181.2.765. View

Esteller M . Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2006; 94(2):179-83. PMC: 2361113. DOI: 10.1038/sj.bjc.6602918. View

Ribas A . Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015; 373(16):1490-2. DOI: 10.1056/NEJMp1510079. View

Kloetzel P . The proteasome and MHC class I antigen processing. Biochim Biophys Acta. 2004; 1695(1-3):225-33. DOI: 10.1016/j.bbamcr.2004.10.004. View

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

DEGEN E, Williams D . Efficient dissociation of the p88 chaperone from major histocompatibility complex class I molecules requires both beta 2-microglobulin and peptide. J Exp Med. 1992; 175(6):1653-61. PMC: 2119236. DOI: 10.1084/jem.175.6.1653. View

10.

Cathro H, Smolkin M, Theodorescu D, Jo V, Ferrone S, Frierson Jr H . Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother. 2009; 59(3):465-72. PMC: 3426234. DOI: 10.1007/s00262-009-0765-9. View

11.

Aspeslagh S, Morel D, Soria J, Postel-Vinay S . Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann Oncol. 2018; 29(4):812-824. DOI: 10.1093/annonc/mdy050. View

12.

Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin B . Expression of MHC II genes. Curr Top Microbiol Immunol. 2006; 290:147-70. DOI: 10.1007/3-540-26363-2_7. View

13.

Cabrera T, Maleno I, Collado A, Lopez Nevot M, Tait B, Garrido F . Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens. 2007; 69 Suppl 1:264-8. DOI: 10.1111/j.1399-0039.2006.00777.x. View

14.

Rock K, Reits E, Neefjes J . Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016; 37(11):724-737. PMC: 5159193. DOI: 10.1016/j.it.2016.08.010. View

15.

Gibney G, Weiner L, Atkins M . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016; 17(12):e542-e551. PMC: 5702534. DOI: 10.1016/S1470-2045(16)30406-5. View

16.

Shin E, Seifert U, Kato T, Rice C, Feinstone S, Kloetzel P . Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006; 116(11):3006-14. PMC: 1592549. DOI: 10.1172/JCI29832. View

17.

Wilson I, Fremont D . Structural analysis of MHC class I molecules with bound peptide antigens. Semin Immunol. 1993; 5(2):75-80. DOI: 10.1006/smim.1993.1011. View

18.

Arnold P, La Gruta N, Miller T, Vignali K, Scott Adams P, Woodland D . The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol. 2002; 169(2):739-49. DOI: 10.4049/jimmunol.169.2.739. View

19.

AKI M, Shimbara N, Takashina M, Akiyama K, Kagawa S, Tamura T . Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem. 1994; 115(2):257-69. DOI: 10.1093/oxfordjournals.jbchem.a124327. View

20.

Ferrone S, Marincola F . Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995; 16(10):487-94. DOI: 10.1016/0167-5699(95)80033-6. View